Colorectal Cancer Screening Clinical Practice Guidelines
Search for other papers by City of Hope Cancer Center in
Current site
Google Scholar
PubMed
Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States. An estimated 104,950 new cases of colon cancer and 40,340 new cases of rectal cancer will occur in the United States in 2005. During the same year, an estimated 56,290 people will die from colon and rectal cancer. Because patients with localized colon cancer have a 90% 5-year survival rate, screening is a critical and particularly effective procedure for colorectal cancer prevention. Screening options include colonoscopy; combined fecal occult blood test (FOBT) and sigmoidoscopy; sigmoidoscopy alone; or double-contrast barium enema.
For the most recent version of the guidelines, please visit NCCN.org
City of Hope (COH) is a leading biomedical research and treatment center and 1 of only 3 National Cancer Institutedesignated Comprehensive Cancer Centers in Los Angeles County. COH has achieved numerous scientific breakthroughs, impacting treatment worldwide.
- • COH conducts more than 300 clinical studies, involving 30% to 40% of its eligible patients, well above the national average.
- • COH has performed more than 7,000 bone marrow and stem cell transplants and today runs one of the largest programs in the world.
- • Numerous lifesaving drugs are based on COH research, including trastuzumab, rituximab, and bevacizumab.
- • COH routinely performs among the highest number of laparoscopic prostatectomies in the U.S.
- • Physicians at COH performed the world's first total marrow irradiation procedure using TomoTherapy technology, and surgeons here were among the first to use robotic technology to treat cancer.
- • COH is the only institution in the world with a clinical study using genetically engineered T-cells to recognize and attack glioma.
Theodore G. Krontiris, MD, PhD (second picture on cover), is Director of the COH Cancer Center and Executive VP, Medical and Scientific Affairs. He serves on numerous advisory panels, including the NIH and NCI, and he is on the board of directors for NCCN.
© 2019-2024 National Comprehensive Cancer Network